Elan Corporation, plc (ELN) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Elan Corporation, plc (ELN)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Qualified Opinion who wrote (4399)	5/24/2003 8:47:15 AM
From: Icebrg	Read Replies (1) of 10345

>>Erik, have you compared Remicade(JNJ) to Antegren for Crohn's ? >> No, I haven't. It is not really possible to do so yet, as we don't have the clinical results for Antegren. We don't know if the drug will be approved for Crohn's, what the label in such a case would look like etc. As the two drugs have completely different modes of action there is actually a distinct possibility that they may complement each other. I suppose you know that there is already a small combination trial on its way. (Evidently without any support from J&J as they are not named as sponsors). clinicaltrials.gov Since I visited the site last time the mode has actually switched to "This study is no longer recruiting patients." status. It was only 60 patients and I suppose it should have been quite attractive to become enrolled. Erik

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next